Save time and get answers to complex questions with AI chat
What are the liver enzyme requirements for starting terbinafineWhen does the apixaban patent expire?Fda livtencity approval letter march 23 2021 regulatory project managerWhen does the patent expire on ibranceAdefovir dipivoxil discount card
See the DrugPatentWatch profile for beyfortus
Yes. Beyfortus (belantamab mafodotin) is FDA‑approved in the United States. It received accelerated approval in 2022 for the treatment of relapsed or refractory multiple myeloma in patients who have received at least four prior lines of therapy, including an immunomodulatory drug, a proteasome inhibitor, and an anti‑CD38 antibody. As of now, that is its sole approved indication in the U.S.
Other Questions About Beyfortus :